Drug Tolerance in Mycobacterium tuberculosis

View/ Open
Date
1999Author
Wallis, Robert S.
Patil, Shripad
Cheon, Seon-Hee
Edmonds, Kay
Phillips, Manijeh
Perkins, Mark D.
Joloba, Moses
Namale, Alice
Johnson, John L.
Teixeira, Lucileia
Dietze, Reynaldo
Siddiqi, Salman
Mugerwa, Roy D.
Eisenach, Kathleen
Ellner, Jerrold J.
Metadata
Show full item recordAbstract
Although Mycobacterium tuberculosis is eradicated rapidly during therapy in some patients with pulmonary tuberculosis, it can persist for many months in others. This study examined the relationship between mycobacterial drug tolerance (delayed killing in vitro), persistence, and relapse. It was performed with 39 fully drug-susceptible isolates from a prospective trial of standard short-course antituberculous therapy with sputum smear-positive, human immunodeficiency virus-uninfected subjects with pulmonary tuberculosis in Brazil and Uganda. The rate of killing in vitro was determined by monitoring the growth index (GI) in BACTEC 12B medium after addition of drug to established cultures and was measured as the number of days required for 99% sterilization. Drugs differed significantly in bactericidal activity, in the following order from greatest to least, rifampin > isoniazid-ethambutol > ethambutol (P < 0.001). Isolates from subjects who had relapses (n 5 2) or in whom persistence was prolonged (n 5 1) were significantly more tolerant of isoniazidethambutol and rifampin than isolates from other subjects (P < 0.01).
URI
https://journals.asm.org/doi/abs/10.1128/AAC.43.11.2600https://nru.uncst.go.ug/xmlui/handle/123456789/784
Collections
- Medical and Health Sciences [3718]